www.ema.europa.eu EMA is advising marketing authorisation holders to submit type IA and type IAIN variations for 2023 no later than Thursday, 30 November 2023. This will enable EMA to acknowledge the validity of the submissions before the Agency's closure between 25 December 2023 and 3...

www.ema.europa.eu The European Commission is launching a selection procedure to appoint independent scientific experts to EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). Six experts will be appointed for a three-year mandate starting on 2 July 2024.The deadline for submission of...

www.ema.europa.eu The European Commission has launched a call for expressions of interest to represent patients’ organisations in EMA's Committee for Orphan Medicinal Products (COMP).The call aims to fill three positions for COMP members nominated by the European Commission to represent...

www.ema.europa.eu EMA’s human medicines committee (CHMP) has recommended authorising an adapted Nuvaxovid vaccine targeting the Omicron XBB.1.5 subvariant of the SARS-CoV-2 virus.The vaccine, known as Nuvaxovid XBB.1.5, is to be used for preventing COVID-19 in adults and children from 12...

www.ema.europa.eu The European Medicines Agency's (EMA) office is closed on Wednesday 1 November and Thursday 2 November 2023 for All Saints’ Day and All Souls’ Day.Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781...

www.ema.europa.eu GLP-1 receptor agonists: available evidence not supporting link with thyroid cancerEMA’s safety committee (PRAC) has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1) - exenatide,...